Other targets. Output area or initiative Target
Other targets. Output area/ initiative Target Associated Strategic Goal
Other targets. Action Associated Strategic Pillar Target Timeframe
Other targets. Output area/ initiative Target Timeframe Associated strategic objective
Other targets. Subject to the terms and conditions of this Agreement, and specifically subject to the limitations set forth in Subsection 4.1.6(b) above, ArQule hereby grants to SB a nonexclusive, worldwide, royalty-free license (without the right to sublicense) under the ArQule Patent Rights and other rights in ArQule Technology to screen ArQule Compounds delivered under the collaboration against Targets in the Field other than Anti-Infective Targets and Anti-Fungal Targets, but only during the Screening Phase.
Other targets. 23 2.6.3 Limitations ........................................... 23 2.7
Other targets. Notwithstanding the foregoing, in the event that GPC identifies another Target to which a Licensed Product binds that is not a GPC Target, then GPC may give notice to MORPHOSYS identifying such Target and notifying MORPHOSYS that it elects to exercise its first negotiation right, as provided hereinbelow, with respect to such Target. Upon receipt of a notice described in the preceding sentence, MORPHOSYS shall, to the extent permitted by contractual arrangements with third parties, negotiate exclusively with GPC with respect to the grant of rights to GPC for the use of the Licensed Product in connection with the Target identified in such notice for a period of not less than 120 days. If, at the end of such 120-day period, GPC and MORPHOSYS have not reached an agreement on the terms of such grant of rights, then MORPHOSYS shall be free to grant such rights to any other party; provided that, MORPHOSYS shall not, for a period of two years, grant such rights to any other party on terms which are, in the aggregate, any more favorable to such party than those last offered by GPC.
Other targets. [***], Lilly and Archemix may include [***].
Other targets. Notwithstanding any other provision in this Agreement, on and after the Restatement Date, each Party and its Affiliates would be free to perform on its own any screening of Compounds against Targets other than the Collaboration Target, and any research or development of Compounds directed against Targets other than the Collaboration Target, except that such right would not include the right to:
(a) use Compounds from the other Party's Chemical Library or Compounds to which the other Party otherwise has proprietary rights,
(b) screen Compounds against the Collaboration Target except to the extent necessary to determine selectivity against Targets other than the Collaboration Target, or
(c) perform research or development on any Compound that is active against the Collaboration Target at the level that would make such a Compound a Hit. Notwithstanding the foregoing, before December 9, 2004, neither Party may collaborate on any of the activities permitted under this Section 2.6.2 with a Third Party who has been granted rights to commercialize Compounds resulting from such activities.
Other targets. In the event that (i) SB fails to identify any Active Compounds from the Compass Array Library in its screens against Anti-Infective Targets and, if applicable, Anti-Fungal Targets and decides not to initiate any additional screening activities of ArQule Compounds against Anti-Infective Targets or Anti-Fungal Targets, or (ii) SB identifies fewer than [*****] Available Compounds from the Compass Array Library in its screens against Anti-Infective Targets and, if applicable, Anti-Fungal Targets, then SB may screen the unused quantities of any ArQule Compounds from the Compass Array Library retained by SB against other Targets for the duration of the Screening Phase; provided that, SB shall give ArQule written notice prior to undertaking such additional screening activities, which notice shall identify such other Targets; and, provided further that before the parties commence such activities, the parties shall negotiate in good faith the commercially reasonable financial terms pertaining to such compounds as described in Section 7.5. and 7.6. below, which terms shall be set forth in a separate agreement. In addition, if SB desires to conduct an optimization project with ArQule on any resulting Licensed Compounds, the parties shall negotiate in good faith the applicable commercially reasonable FTE rate unless the project is a substitute project as described in Subsection 4.2.6.
